Warning: UK E-liquids may Contain Dangerous Synthetic Drugs

Regulations by 2FIRSTS.ai
Feb.08.2024
Warning: UK E-liquids may Contain Dangerous Synthetic Drugs
Warning: Some e-liquids sold in the UK may contain illicit substances, including synthetic cannabinoids known as "spice."

Recently, health experts in Wales, UK issued a warning claiming that e-liquids being sold in the country may contain synthetic marijuana compounds known as "Spice". They argue that these illicit e-liquids have extremely potent medicinal effects and pose a danger to users who opt for counterfeit prescription drug e-cigarette products.

 

Some e-liquids consumed by UK consumers in their daily lives contain cannabis, CBD, or tetrahydrocannabinol (THC). Recently, WEDINOS, the only nationwide drug testing service in the UK, conducted tests and found that certain e-liquids being sold in the market also contain a potent synthetic drug known as synthetic cannabinoid receptor agonists (SCRAs), sometimes referred to as "spice." Based on these test results, the Welsh public health department has stated that some of these products being sold in the UK pose significant risks to consumers.

 

Synthetic cannabinoid receptor agonists (SCRAs) are a group of compounds associated with significant health issues, ranging from respiratory difficulties to psychiatric episodes. The latest data from WEDINOS, an organization, reveals that out of the 196 liquid samples submitted to them in 2023, 75 samples (almost one-third) contained one or more SCRA compounds.

 

These samples were purchased in the form of cannabis, CBD, or THC e-liquids. Among the number of hospitalizations due to illicit drugs, opioids are the most prevalent, followed by cannabis and synthetic cannabinoids such as Spice. Opioids also remain the most likely type of drug to be associated with drug-related deaths.

 

Experts from the agency have expressed concern over a significant increase in the number of counterfeit prescription drug samples they have received, which have been contaminated with potentially hazardous substances. They have also frequently detected the presence of benzodiazepines, a class of drugs commonly purchased as prescription medication, such as diazepam and hydrocodone.

 

These highly concentrated synthetic opioid medications can pose a threat to life, and there is a significant risk of overdosing. Last year, WEDINOS received 90 samples containing nitrous nitrogen drugs, with nearly 50% purchased under the mistaken belief of being an anti-anxiety medication called diazepam.

 

Professor Rick Lines, the Head of Drug Abuse at the Welsh Public Health Department, has highlighted the need to recognize the increased risk of medication overdose associated with high-concentration drugs. "Our concern is that people who purchase e-cigarettes online may not actually be receiving what they believe they are getting," he cautioned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
As regulation tightens and innovation matures, competition in the new tobacco industry is shifting. In its 2026 Global Product Trends in the New Tobacco Industry report, 2Firsts examines how heated tobacco, nicotine pouches, and vape products are moving beyond feature-driven upgrades toward system-level design, where experience management, compliance structure, and engineering capability increasingly shape long-term competition.
Jan.13 by 2Firsts Perspectives
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
Philip Morris International reported full-year 2025 results on February 6, with smoke-free products accounting for 41.5% of adjusted net revenues, up from 38.7% a year earlier. Total net revenues rose 7.3% to $40.65 billion, while shipment volumes increased 1.4%, widening the gap between revenue and volume growth. Cigarette shipments declined as smoke-free volumes rose 12.8%, driven by heated tobacco, oral nicotine and e-vapor products. Results were released alongside a 9:00 a.m. EST webcast.
Feb.06
China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China’s tobacco authorities used their annual industry meeting in Beijing to outline new growth drivers for 2026, highlighting cigarette innovation, domestic cigars, overseas business expansion and multi-purpose tobacco applications.
Special Report
Jan.20
Malaysia’s MOH aims to implement a vape ban in 2026, starting with open pod systems
Malaysia’s MOH aims to implement a vape ban in 2026, starting with open pod systems
Bernama (Malaysia’s national news agency) reported that Health Minister Datuk Seri Dr Dzulkefly Ahmad said the Ministry of Health aims to implement a vape ban this year, beginning with open pod systems, and will not compromise on enforcing the Control of Smoking Products for Public Health Act 2024 (Act 852).
Jan.06 by 2FIRSTS.ai
RJ Reynolds asks ITC to investigate alleged vape restriction violations by Heaven Gifts network
RJ Reynolds asks ITC to investigate alleged vape restriction violations by Heaven Gifts network
R.J. Reynolds Tobacco Co. has asked the U.S. International Trade Commission to open a Section 337 investigation into Heaven Gifts International — the umbrella company behind Elf Bars and Geek Bars — its subsidiaries and nine U.S. distributors.
Jan.16 by 2FIRSTS.ai
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China’s Ministry of Finance and State Taxation Administration have announced adjustments to export tax rebate policies, placing nicotine-containing non-combustible inhalation products within the scope of items subject to rebate cancellation. The measures will take effect from April 1, 2026.
Regulations
Jan.10